Table 1.

FDA-approved ADCs for the treatment of solid tumors

	Target	Payload	Linker	DAR	Indications
Trastuzumab emtansine (T-DM1)	HER2	Maytansine (microtubule inhibitor)	Non-cleavable thioether linker	3.5	HER2-positive mBC pretreated with trastuzumab and a taxane; HER2-positive early BC with residual disease after neoadjuvant trastuzumab and taxanes
Trastuzumab deruxtecan (T-DXd)	HER2	Deruxtecan (topoisomerase inhibitor)	Protease-cleavable linker	8	HER2-positive mBC progressing to two or more prior anti-HER2-based regimens in the metastatic setting
Enfortumab vedotin (EV)	Nectin-4	Monomethyl auristatin E (microtubule inhibitor)	Protease-cleavable linker	3.8	Locally advanced/metastatic UC previously treated with a PD-(L)1 and a platinum-based chemotherapy in the (neo)adjuvant or metastatic setting
Sacituzumab govitecan (SG)	Trop-2	SN-38 (topoisomerase inhibitor)	Hydrolysable linker	7.5	Triple-negative mBC (who have received at least two prior therapies for metastatic disease)